The European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.
Pratap Khedkar, managing principal for ZS’ global pharmaceuticals practice, talks to Pharm Exec about what companies need to focus on to achieve and optimize digital transformation in 2021 and beyond.
With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.
Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.
Key takeaways on digital health from the 2021 JP Morgan Healthcare conference.
Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.
Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
Sameer Lal and Sandeep Gantotti discuss the building of a next-gen medical information practice to modernize its operations and unlock its value to the wider organization and to HCPs.
Industry’s tardy shift to cloud-based solutions looks set to gather pace in 2021.
Going beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.
The pandemic has raised the stakes for companies pursuing new data-harnessing capabilities in contract management and KPI benchmarking and tracking.
To realize the promise of genomics, pharma must be prepared to mine the data more effectively.
Owning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.
Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.
While patient support providers play an important role in keeping patients on therapy, biopharma companies have a great opportunity to push analytical sophistication beyond what many of these providers currently offer.
Ferdi Steinmann looks at pharma's current relationship with AI and how it is set to evolve.
How technology can maximize use of manufacturer copay and patient assistance programs.
Todd Nichols, chief commercial officer of Alkermes, gives his top three recommendations for going all-in to digitally transform the frontline sales team.
The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Whether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.
Following her own experience, a health tech entrepreneur turned to AI to better guide other patients through their treatment journeys.
Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.
Companies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.
Following the introduction this week MyVeeva for Doctors, Veeva’s Paul Shawah discusses the background to the product and the role biopharma companies will play in its ongoing development.
Digital engagement is becoming the new normal, but it can inhibit the individual connection that is foundational to building long-term customer relationships. How can reps, brand teams, and medical science liaisons strike the right balance of personal and non-personal engagement? The next generation of AI has an answer, writes Derek Choy.
